Silevertinib

AssetAlso called BDTX - 1535

Inhibits mutant EGFR signaling to suppress tumor growth.

Stage
Phase 2
Modality
Small molecule
Target
EGFR
2
Indications
0
Trials
1
Developer

Named in the news on Nov 9, 2026. news.google.com

Indications

2
  • Non-small cell lung cancer with EGFR non-classical mutations

    Phase 2, news.google.com, Nov 9, 2026

  • Non-small cell lung cancer

    Clinical, no phase, SEC filing, Mar 19, 2025

In the full profile

  • Target and mechanism1
  • Owner and partners1
  • Evidence for its targets1
  • Competitors12
  • Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets